Back to homepage

Tag "adalimumab"

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Authors: Daniela Opris-Belinski MD, PhD, Shandor F Erdes MD, PhD, Simeon Grazio MD, PhD, Ladislav Šenolt MD, PhD, Maja Hojnik MD, PhD, Orsolya Nagy MD, PhD, Diana Marina BSc, Sándor Szántó MD, PhD, DSc

This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis in five Central and Eastern Europe countries.

More▸

The cost of biologics for psoriasis is increasing

Authors: Judy Cheng, Steven R Feldman

Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

More▸